

3 Relevante Originalarbeiten

1. *Paetsch I, *Jahnke C, Nehrke K, Schnackenburg B, Bornstedt A, Gebker R, Fleck E, Nagel E. (*both first authors contributed equally to the work) A new approach for rapid assessment of the cardiac rest period for coronary MRA. *J Cardiovasc Magn Reson*. 2005;7(2):395-399. IF: 1.9
2. Jahnke C, Paetsch I, Schnackenburg B, Bornstedt A, Gebker R, Fleck E, Nagel E. Coronary MR angiography with steady-state free precession: individually adapted breath-hold technique versus free-breathing technique. *Radiology*. Sep 2004;232(3):669-676. IF: 5.1
3. Huber ME, Paetsch I, Schnackenburg B, Bornstedt A, Nagel E, Fleck E, Boesiger P, Maggioni F, Cavagna FM, Stuber M. Performance of a new gadolinium-based intravascular contrast agent in free-breathing inversion-recovery 3D coronary MRA. *Magn Reson Med*. Jan 2003;49(1):115-121. IF: 3.3
4. Paetsch I, Huber ME, Bornstedt A, Schnackenburg B, Boesiger P, Stuber M, Fleck E, Cavagna F, Nagel E. Improved three-dimensional free-breathing coronary magnetic resonance angiography using gadocoletic acid (B-22956) for intravascular contrast enhancement. *J Magn Reson Imaging*. Aug 2004;20(2):288-293. IF: 2.9
5. Paetsch I, Jahnke C, Barkhausen J, Spuentrup E, Cavagna F, Schnackenburg B, Huber M, Stuber M, Fleck E, Nagel E. Detection of coronary stenoses with contrast enhanced, three-dimensional free breathing coronary MR angiography using the gadolinium-based intravascular contrast agent gadocoletic acid (B-22956). *J Cardiovasc Magn Reson*. 2006;8(3):509-516. IF: 1.9
6. Wahl A, Paetsch I, Roethemeyer S, Klein C, Fleck E, Nagel E. High-dose dobutamine-atropine stress cardiovascular MR imaging after coronary revascularization in patients with wall motion abnormalities at rest. *Radiology*. Oct 2004;233(1):210-216. IF: 5.1

7. Wahl A, Paetsch I, Gollesch A, Roethemeyer S, Foell D, Gebker R, Langreck H, Klein C, Fleck E, Nagel E. Safety and feasibility of high-dose dobutamine-atropine stress cardiovascular magnetic resonance for diagnosis of myocardial ischaemia: experience in 1000 consecutive cases. *Eur Heart J*. Jul 2004;25(14):1230-1236. IF: 6.2
8. Paetsch I, Jahnke C, Wahl A, Gebker R, Neuss M, Fleck E, Nagel E. Comparison of dobutamine stress magnetic resonance, adenosine stress magnetic resonance, and adenosine stress magnetic resonance perfusion. *Circulation*. Aug 17 2004;110(7):835-842. IF: 12.6
9. Paetsch I, Jahnke C, Ferrari VA, Rademakers FE, Pellikka PA, Hundley WG, Poldermans D, Bax JJ, Wegscheider K, Fleck E, Nagel E. Determination of interobserver variability for identifying inducible left ventricular wall motion abnormalities during dobutamine stress magnetic resonance imaging. *Eur Heart J*. June 2, 2006 2006;27(12):1459-1464. IF: 7.3
10. Paetsch I, Foll D, Kaluza A, Luechinger R, Stuber M, Bornstedt A, Wahl A, Fleck E, Nagel E. Magnetic resonance stress tagging in ischemic heart disease. *Am J Physiol Heart Circ Physiol*. Jun 2005;288(6):H2708-2714. IF: 3.5
11. Jahnke C, Nagel E, Gebker R, Kokocinski T, Kelle S, Manka R, Fleck E, Paetsch I. Prognostic Value of Cardiac Magnetic Resonance Stress Tests. Adenosine Stress Perfusion and Dobutamine Stress Wall Motion Imaging. *Circulation*. 2007:CIRCULATIONAHA.106.652016. IF: 11.6

Impact factor (gesamt)

IF: 61.4